Protalix BioTherapeutics Inc (PLX)
1.69
+0.03
(+1.81%)
USD |
NYAM |
Nov 22, 16:00
1.70
+0.01
(+0.59%)
Pre-Market: 20:00
Protalix BioTherapeutics Revenue (TTM): 45.67M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 45.67M |
| June 30, 2024 | 38.05M |
| March 31, 2024 | 59.65M |
| December 31, 2023 | 65.49M |
| September 30, 2023 | 63.62M |
| June 30, 2023 | 67.46M |
| March 31, 2023 | 41.14M |
| December 31, 2022 | 47.64M |
| September 30, 2022 | 47.57M |
| June 30, 2022 | 45.44M |
| March 31, 2022 | 43.12M |
| December 31, 2021 | 38.35M |
| September 30, 2021 | 49.30M |
| June 30, 2021 | 48.03M |
| March 31, 2021 | 52.57M |
| December 31, 2020 | 62.90M |
| September 30, 2020 | 61.16M |
| June 30, 2020 | 64.62M |
| March 31, 2020 | 65.90M |
| December 31, 2019 | 54.69M |
| September 30, 2019 | 47.29M |
| June 30, 2019 | 45.37M |
| March 31, 2019 | 37.96M |
| December 31, 2018 | 34.24M |
| September 30, 2018 | 28.19M |
| Date | Value |
|---|---|
| June 30, 2018 | 23.38M |
| March 31, 2018 | 24.90M |
| December 31, 2017 | 21.08M |
| September 30, 2017 | 18.85M |
| June 30, 2017 | 16.00M |
| March 31, 2017 | 11.41M |
| December 31, 2016 | 9.199M |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | -5.889M |
| June 30, 2015 | -3.518M |
| March 31, 2015 | -2.168M |
| December 31, 2014 | 3.523M |
| September 30, 2014 | 3.385M |
| June 30, 2014 | 3.037M |
| March 31, 2014 | 3.415M |
| December 31, 2013 | 0.00 |
| September 30, 2013 | 10.44M |
| June 30, 2013 | 12.47M |
| March 31, 2013 | 34.66M |
| December 31, 2012 | 34.42M |
| September 30, 2012 | 35.06M |
| June 30, 2012 | 30.57M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
38.05M
Minimum
Jun 2024
67.46M
Maximum
Jun 2023
53.12M
Average
50.93M
Median
Revenue (TTM) Benchmarks
| Accuray Inc | 444.20M |
| Aethlon Medical Inc | -- |
| AIM ImmunoTech Inc | 0.19M |
| Perspective Therapeutics Inc | -- |
| Armata Pharmaceuticals Inc | -- |